Clinical AI Needs Governance, Not Another Pilot

Hospitals are not short of AI pilots. They are short of a mechanism for deciding what any of the pilots meant.

That distinction explains most of what is going wrong in health system AI programmes right now, and it is not a technology problem.

The pattern

An executive sees a persuasive demo and buys. A pilot runs in one department for four months. The evaluation comes back inconclusive — for three reasons, all of which were determined before the pilot started.

Nobody defined the outcome measure in advance, so the only evidence available afterwards is how people felt. The control group was contaminated, because enthusiastic early adopters shared access and departments compared notes. And the underlying data could not have supported the analysis regardless.

So the decision is made on sentiment. The tool is renewed because people liked it, or dropped because a vocal minority did not. Nothing was learned either way.

Run this three times and the organisation concludes that clinical AI does not work. What actually happened is that it was never measured, and now there is an institutional belief formed from three experiments that were incapable of producing an answer.

What is actually missing

Not more pilots. A body with authority.

In practice that means clinical leadership, informatics, compliance, and someone explicitly accountable for equity, meeting on a schedule, with a written standard covering what evidence a tool must present before deployment and what monitoring it must carry afterwards.

The word that matters is authority. Without the power to refuse a deployment and to withdraw an existing one, it is a review meeting, and tools will simply be adopted around it.

Organisations that skip this do not end up with no clinical AI. They end up with clinical AI adopted departmentally, invisibly, with no mechanism for pulling it back when something goes wrong. That is the worst available position — the exposure exists and the visibility does not.

Why local evaluation is not optional

Every vendor shows validation results. Almost none were generated on your patients.

Prevalence alone changes what a threshold means. A model with 85% sensitivity and 90% specificity produces roughly one true positive per three alerts at 5% prevalence, and about one per twelve at 1%. The model has not changed at all. The experience of the clinician receiving those alerts has changed completely, and that experience decides whether the tool survives contact with a real ward.

Documentation practice shifts the input distribution. Coding conventions differ, and the ten to twenty percent of local codes that never mapped cleanly to standard terminology concentrate in exactly the newer, specialty-specific areas where models tend to get applied.

None of this is a vendor failure. It is why the evaluation has to be local.

Drift is the silent one

A model accurate at go-live degrades gradually while clinicians continue trusting it at the original level. Nothing is designed to notice, because monitoring is usually specified as a launch requirement rather than an ongoing one.

Schedule re-evaluation — quarterly is a reasonable default — on a fresh local sample, stratified the same way. Define in advance what degradation triggers a review and who acts on it. If nobody holds that authority, the monitoring is decorative.

What to do with a limited budget

Not another pilot. A focused six-to-eight week assessment establishing what your data can currently support for two or three use cases with real clinical or financial upside, and what closing the gap would cost.

It produces no demo, which makes it hard to fund. It is also the difference between a programme that generates evidence and one that generates three inconclusive results and a resigned executive team.

Full article covering data readiness, interoperability, ambient documentation, security and how to vet a consulting partner: Healthcare IT Consulting Services: What Actually Moves the Needle in 2026

Frequently Asked Questions

Who should sit on a clinical AI governance body?

Clinical leadership, informatics, compliance, and someone explicitly accountable for equity. The critical property is authority to refuse a deployment and withdraw an existing one — without it, the group has no function.

How is this different from an existing IT governance committee?

Scope and expertise. Traditional committees evaluate whether a system can be supported and integrated. Clinical AI additionally requires judging evidence quality, subgroup performance, and ongoing monitoring — which needs clinical and statistical literacy that standard committees usually lack.

What evidence should a tool present before deployment?

Local evaluation on your own data with defined ground truth, performance stratified by the subgroups where failure would be most consequential, a stated operating point with its alert burden, and a monitoring plan with a named owner.

Can a small hospital do this without a dedicated team?

Yes, at reduced scope. A standing group meeting monthly, a written evidence standard, and one adjudicated local sample per deployed tool covers most of the risk. The governance discipline scales down better than the data engineering does.

What about tools already deployed without review?

Inventory them first — this usually surprises people. Then triage by potential harm, and evaluate the highest-risk ones retrospectively. Withdrawal is easier to justify once an inventory shows how many are running unmonitored.

Does this slow down adoption?

It slows down unevaluated adoption, which is the point. Organisations with functioning governance generally deploy fewer tools and keep them longer, because the ones that survive review are the ones that work.